MIS51ONNCT03992430
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 29 versions: 28 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 12 words Show 4 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Oct 31, 2026 to Sep 7, 2026
- Secondary endpoints: details revised at 1 of 7 entries
- Site details revised at 11 of 59 sites
Notable Primary and study completion dates: Nov 30, 2024 to Oct 31, 2026v27 Show 4 more changesShow less
- Eligibility criteria expanded, about 10 words
- Primary endpoints: 2 to 3
- Secondary endpoints revised (7)
- Study title shortened, about 1 word
- Minor Study sites: 58 to 59v26
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 154 to confirmed 160
- Study sites: 60 to 58
- Minor Study sites: 54 to 60v24
Show 22 earlier versionsHide 22 earlier versions
- Minor Study sites: 51 to 54v23
- Minor Study sites: 50 to 51v22
- Minor Study sites: 52 to 50v21
- Minor Study sites: 51 to 52v20
- Minor Study sites: 48 to 51v19
- Minor Study sites: 45 to 48v18
- Minor Study sites: 30 to 45v17
- Minor Study sites: 28 to 30v16
- Minor Study sites: 23 to 28v15
- Minor Study sites: 21 to 23v14
- Minor Study sites: 18 to 21v13
- Minor Study sites: 15 to 18v12
- Minor Study sites: 13 to 15v11
- Notable Primary and study completion dates: Feb 28, 2026 to Nov 30, 2024
- Study sites: 10 to 13
- Minor Study sites: 8 to 10v9
Notable Trial status: Active, Not Recruiting to Recruitingv8 Show 7 more changesShow less
- Eligibility criteria expanded, about 85 words
- Primary endpoints: 5 to 2
- Enrollment target: 152 to 154
- Primary and study completion dates: Feb 2026 to Feb 28, 2026
- Secondary endpoints: 6 to 7
- Study sites revised (8)
- Study title expanded, about 1 word
- Notable Primary and study completion dates: Oct 2024 to Feb 2026
- Trial status: Recruiting to Active, Not Recruiting
- Study sites: 7 to 8
- Minor Site contacts updated at 1 of 7 sitesv6
- Notable Start date changed from estimate of Jan 2020 to Jul 13, 2020
- Eligibility criteria expanded, about 15 words
- Study sites: 2 to 7
- Secondary endpoints: details revised at 1 of 6 entries
- Minor Study sites: 1 to 2
- Start date: Dec 2019 to Jan 2020
- Minor Start date: Dec 5, 2019 to Dec 2019v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Aug 2019 to Dec 5, 2019
- Study sites: 0 to 1
- Study title expanded, about 1 word
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Participants will receive eteplirsen 100 mg/kg once weekly for at least 4 weeks, followed by eteplirsen 200 mg/kg once weekly for at least 4 weeks.
Randomized participants will receive eteplirsen 30 mg/kg once weekly for up to 144 weeks.
Randomized participants will receive eteplirsen 100 mg/kg once weekly for up to 144 weeks.
Randomized participants will receive eteplirsen 200 mg/kg once weekly for up to 144 weeks.
Drugs: Eteplirsen
Sites
59 sites in 26 countries
India 8, Jordan 4, South Korea 4, Colombia 3, France 3, Germany 3, Serbia 3, United Kingdom 3, United States 3, Czechia 2, Italy 2, Mexico 2, Netherlands 2, Norway 2, Spain 2, Taiwan 2, Turkey (Türkiye) 2, Denmark 1, Greece 1, Hungary 1, Ireland 1, New Zealand 1, Poland 1, Romania 1, Slovenia 1, Switzerland 1